Nippon Gases Italia and Noxtec Development join forces to develop and strengthen a company dedicated to design, produce and distribute state-of-the-art medical devices worldwide.
This partnership stems from the desire of the two companies to embark together on a path, already started separately in recent years, aimed at the technological improvement of devices used in inhaled nitric oxide therapies, thanks to a continuous exchange of information with university and hospital structures, in order to improve their effectiveness and evaluate the development of new applications.
The ambition of the new venture is to meet the needs of the nitric oxide therapy market, which has grown exponentially in recent years, concentrating first in neonatal intensive care units, then in pediatric and adult settings, and finally playing a key role during the last 2 years in the treatment of Covid-19 patients.
The increased use of Nitric Oxide, a powerful vasodilator, is linked not only to its effectiveness in terms of therapy response times, but above all to its localized action in the cardiopulmonary area, lowering blood pressure rapidly and avoiding interactions with other areas of the human body.
The new joint venture will combine Noxtec Development's high-level expertise in the development of new high-tech medical products with Nippon Gases' 100 years of experience in the production of medical gases. Nippon Gases, acquiring the controlling share of the company, will give wide geographical reach and visibility of the new project all over the world with the goal of exploring new geographies and the aim to create social value through innovative solutions.
nitric oxide therapy equipment will be just one of the milestones of the new
company, which will focus on innovation to improve the quality of medical
products and services for healthcare providers and patients, enhancing human
well-being and contributing to a more sustainable future. The company will be a
reference in the medical sector, relying on a competent, experienced and
dedicated team focused
the core values of both partners: reliability, quality, safety and
Noxtec Development, established in 2017 to develop new products in the high-tech medical sector, has over the years developed a strong specialization in the field of inhaled nitric oxide therapies.
The first device for inhaled nitric oxide therapies, developed by Noxtec, has made it possible not only to monitor and manage the therapy in constant doses as the patient's respiratory flow changes, but also to improve the safe management of the device through remote control systems and automatic calibration.